CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Perspective Therapeutics reports 75% disease control rate at 3.0 mCi dose in melanoma trial

By Public Technologies
  • Perspective Therapeutics presented interim Phase 1/2a results for lapemelanotide zapixetar (VMT01) in heavily pretreated advanced melanoma patients at SITC 2026.
  • The investigational monotherapy produced partial tumor responses and sustained disease stabilization in some patients.
  • No treatment-related serious adverse events or adverse event-related treatment discontinuations occurred among 20 patients through the September 18, 2026, data cutoff.
  • No dose-limiting toxicities were reported; severe adverse events were considered unrelated to treatment.
  • Continued evaluation and dose optimization will inform the program's next development steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061200PRIMZONEFULLFEED9872341) on November 06, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk